Olstein Capital Management L.P. Sells 17,023 Shares of Charles River Laboratories International, Inc. (CRL)

Olstein Capital Management L.P. lessened its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 22.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 60,112 shares of the medical research company’s stock after selling 17,023 shares during the period. Olstein Capital Management L.P. owned about 0.13% of Charles River Laboratories International worth $6,493,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Alps Advisors Inc. grew its position in shares of Charles River Laboratories International by 0.3% in the second quarter. Alps Advisors Inc. now owns 5,350 shares of the medical research company’s stock valued at $541,000 after purchasing an additional 14 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in Charles River Laboratories International by 0.5% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,953 shares of the medical research company’s stock worth $703,000 after buying an additional 33 shares in the last quarter. Bbva Compass Bancshares Inc. grew its position in Charles River Laboratories International by 0.8% during the second quarter. Bbva Compass Bancshares Inc. now owns 6,004 shares of the medical research company’s stock worth $607,000 after buying an additional 50 shares in the last quarter. World Asset Management Inc grew its position in Charles River Laboratories International by 2.2% during the second quarter. World Asset Management Inc now owns 2,762 shares of the medical research company’s stock worth $279,000 after buying an additional 59 shares in the last quarter. Finally, M&T Bank Corp lifted its stake in Charles River Laboratories International by 1.8% during the second quarter. M&T Bank Corp now owns 4,358 shares of the medical research company’s stock worth $441,000 after purchasing an additional 76 shares during the last quarter. Institutional investors and hedge funds own 96.27% of the company’s stock.

CRL has been the subject of a number of research reports. Credit Suisse Group reiterated a “neutral” rating and issued a $112.00 price target (up from $95.00) on shares of Charles River Laboratories International in a research note on Monday, October 16th. Zacks Investment Research upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $129.00 price objective for the company in a report on Tuesday, October 24th. ValuEngine downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Jefferies Group restated a “buy” rating and issued a $120.00 price objective on shares of Charles River Laboratories International in a report on Tuesday, September 12th. Finally, Royal Bank Of Canada started coverage on Charles River Laboratories International in a report on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 price target for the company. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $106.63.

Charles River Laboratories International, Inc. (NYSE CRL) opened at $103.13 on Friday. Charles River Laboratories International, Inc. has a 1 year low of $72.07 and a 1 year high of $119.05. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.62 and a current ratio of 1.88. The company has a market cap of $4,822.35, a P/E ratio of 20.00, a price-to-earnings-growth ratio of 1.62 and a beta of 0.89.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Thursday, November 9th. The medical research company reported $1.30 EPS for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. The company had revenue of $464.23 million for the quarter, compared to analysts’ expectations of $458.93 million. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. Charles River Laboratories International’s revenue was up 9.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.18 EPS. sell-side analysts forecast that Charles River Laboratories International, Inc. will post 5.13 earnings per share for the current year.

In other news, insider Bradley Nixon Scharfe sold 1,000,000 shares of the business’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $0.27, for a total transaction of $270,000.00. Also, insider Davide Molho sold 6,165 shares of the business’s stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $110.00, for a total transaction of $678,150.00. The disclosure for this sale can be found here. Insiders purchased a total of 10,500 shares of company stock valued at $2,885 over the last quarter. 2.20% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Olstein Capital Management L.P. Sells 17,023 Shares of Charles River Laboratories International, Inc. (CRL)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/08/olstein-capital-management-l-p-sells-17023-shares-of-charles-river-laboratories-international-inc-crl.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply